SG11202112021QA - Materials and methods for modulating t cell mediated immunity - Google Patents
Materials and methods for modulating t cell mediated immunityInfo
- Publication number
- SG11202112021QA SG11202112021QA SG11202112021QA SG11202112021QA SG11202112021QA SG 11202112021Q A SG11202112021Q A SG 11202112021QA SG 11202112021Q A SG11202112021Q A SG 11202112021QA SG 11202112021Q A SG11202112021Q A SG 11202112021QA SG 11202112021Q A SG11202112021Q A SG 11202112021QA
- Authority
- SG
- Singapore
- Prior art keywords
- modulating
- materials
- methods
- cell mediated
- mediated immunity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962844976P | 2019-05-08 | 2019-05-08 | |
| US201962844970P | 2019-05-08 | 2019-05-08 | |
| US201962844959P | 2019-05-08 | 2019-05-08 | |
| US201962844966P | 2019-05-08 | 2019-05-08 | |
| US201962844995P | 2019-05-08 | 2019-05-08 | |
| PCT/US2020/031749 WO2020227457A1 (en) | 2019-05-08 | 2020-05-07 | Materials and methods for modulating t cell mediated immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112021QA true SG11202112021QA (en) | 2021-11-29 |
Family
ID=73051172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112021QA SG11202112021QA (en) | 2019-05-08 | 2020-05-07 | Materials and methods for modulating t cell mediated immunity |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11667712B2 (en) |
| EP (1) | EP3965818A4 (en) |
| JP (1) | JP2022533538A (en) |
| KR (1) | KR20220017892A (en) |
| CN (1) | CN113966231A (en) |
| AU (1) | AU2020267504A1 (en) |
| BR (1) | BR112021022089A2 (en) |
| CA (1) | CA3139508A1 (en) |
| CL (1) | CL2021002905A1 (en) |
| CO (1) | CO2021015998A2 (en) |
| CR (1) | CR20210548A (en) |
| DO (1) | DOP2021000229A (en) |
| EC (1) | ECSP21087921A (en) |
| IL (1) | IL287817A (en) |
| JO (1) | JOP20210297A1 (en) |
| MA (1) | MA55903A (en) |
| MX (1) | MX2021013532A (en) |
| PE (1) | PE20220763A1 (en) |
| SG (1) | SG11202112021QA (en) |
| TW (1) | TW202108618A (en) |
| WO (1) | WO2020227457A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| KR20230169950A (en) | 2021-02-26 | 2023-12-18 | 라바 테라퓨틱스 엔.브이. | Antibodies that bind to CD123 and gamma-delta T cell receptors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2005538682A (en) | 2001-12-03 | 2005-12-22 | アブジェニックス・インコーポレーテッド | Antibody against carboxic anhydrase IX (CAIX) tumor antigen |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| DK3050963T3 (en) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Process for producing polypeptide by arrangement control |
| DE102005028778A1 (en) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| JP2009541275A (en) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | Production of bispecific antibodies |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP2347038A4 (en) | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | Methods of humanizing and affinity-maturing antibodies |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP3211094A3 (en) * | 2009-09-03 | 2017-11-01 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| SG10201800757TA (en) | 2010-04-20 | 2018-02-27 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| BR112013002831A2 (en) | 2010-08-05 | 2016-11-01 | Anaptysbio Inc | antibodies directed against il-17 |
| PL2635607T3 (en) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| DK2748201T3 (en) * | 2011-08-23 | 2018-02-12 | Roche Glycart Ag | BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| SI2794658T1 (en) | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecific antibody molecule |
| CA2926859A1 (en) * | 2013-10-25 | 2015-04-30 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| MA53355A (en) | 2015-05-29 | 2022-03-16 | Agenus Inc | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF |
| CA3048601A1 (en) | 2016-12-26 | 2018-07-05 | Kyowa Hakko Kirin Co., Ltd. | Antibody which binds to myelin oligodendrocyte glycoprotein |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| US10519236B2 (en) * | 2018-01-23 | 2019-12-31 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| TW202144415A (en) | 2020-02-27 | 2021-12-01 | 美商健生生物科技公司 | Materials and methods for modulating an immune response |
| US20210284731A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| CN116390950A (en) | 2020-10-28 | 2023-07-04 | 詹森生物科技公司 | Compositions and methods for modulating delta gamma chain mediated immunity |
-
2020
- 2020-05-07 SG SG11202112021QA patent/SG11202112021QA/en unknown
- 2020-05-07 KR KR1020217036132A patent/KR20220017892A/en unknown
- 2020-05-07 CR CR20210548A patent/CR20210548A/en unknown
- 2020-05-07 WO PCT/US2020/031749 patent/WO2020227457A1/en unknown
- 2020-05-07 BR BR112021022089A patent/BR112021022089A2/en unknown
- 2020-05-07 AU AU2020267504A patent/AU2020267504A1/en active Pending
- 2020-05-07 EP EP20801607.1A patent/EP3965818A4/en active Pending
- 2020-05-07 MA MA055903A patent/MA55903A/en unknown
- 2020-05-07 CN CN202080043002.2A patent/CN113966231A/en active Pending
- 2020-05-07 TW TW109115171A patent/TW202108618A/en unknown
- 2020-05-07 CA CA3139508A patent/CA3139508A1/en active Pending
- 2020-05-07 JP JP2021565723A patent/JP2022533538A/en active Pending
- 2020-05-07 PE PE2021001851A patent/PE20220763A1/en unknown
- 2020-05-07 US US16/869,401 patent/US11667712B2/en active Active
- 2020-05-07 MX MX2021013532A patent/MX2021013532A/en unknown
- 2020-05-07 JO JOP/2021/0297A patent/JOP20210297A1/en unknown
-
2021
- 2021-11-03 IL IL287817A patent/IL287817A/en unknown
- 2021-11-04 DO DO2021000229A patent/DOP2021000229A/en unknown
- 2021-11-04 CL CL2021002905A patent/CL2021002905A1/en unknown
- 2021-11-26 CO CONC2021/0015998A patent/CO2021015998A2/en unknown
- 2021-12-03 EC ECSENADI202187921A patent/ECSP21087921A/en unknown
-
2023
- 2023-04-25 US US18/306,401 patent/US20240150464A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021022089A2 (en) | 2022-02-08 |
| DOP2021000229A (en) | 2022-07-31 |
| WO2020227457A1 (en) | 2020-11-12 |
| TW202108618A (en) | 2021-03-01 |
| PE20220763A1 (en) | 2022-05-16 |
| MA55903A (en) | 2022-03-16 |
| JP2022533538A (en) | 2022-07-25 |
| CA3139508A1 (en) | 2020-11-12 |
| ECSP21087921A (en) | 2022-01-31 |
| CO2021015998A2 (en) | 2021-12-10 |
| EP3965818A1 (en) | 2022-03-16 |
| IL287817A (en) | 2022-01-01 |
| CN113966231A (en) | 2022-01-21 |
| US20240150464A1 (en) | 2024-05-09 |
| CL2021002905A1 (en) | 2022-06-17 |
| AU2020267504A1 (en) | 2021-12-02 |
| KR20220017892A (en) | 2022-02-14 |
| CR20210548A (en) | 2022-02-11 |
| US11667712B2 (en) | 2023-06-06 |
| US20210032338A1 (en) | 2021-02-04 |
| MX2021013532A (en) | 2022-02-11 |
| EP3965818A4 (en) | 2023-05-31 |
| JOP20210297A1 (en) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3537765A4 (en) | Switching method and apparatus | |
| EP3555422A4 (en) | Methods and devices for evaluating the contents of materials | |
| EP3557908A4 (en) | Cell handover method and apparatus | |
| EP3640322A4 (en) | Cell culturing method and device | |
| EP3374279A4 (en) | Tamper-evident container and method | |
| EP3300298A4 (en) | Method and apparatus for switching vnf | |
| EP3506686A4 (en) | State switching method and apparatus | |
| EP3614707A4 (en) | State switching method and apparatus | |
| EP3365243A4 (en) | Containers and closures | |
| IL287817A (en) | Materials and methods for modulating t cell mediated immunity | |
| EP3145246A4 (en) | Bearer switching control device and control method | |
| EP3141322A4 (en) | Bonding material and bonding method using same | |
| EP3360821A4 (en) | Discharge container and method for recycling same | |
| EP3195342A4 (en) | Transparent electrode materials and methods for forming same | |
| EP3548182A4 (en) | Apparatus and method for separating materials using stratification | |
| EP3321351A4 (en) | Cell-holding container and cell culture method using same | |
| EP3739952A4 (en) | Cell type indication method and apparatus | |
| EP3108575A4 (en) | Zero voltage switching detection apparatus and method | |
| EP3198007A4 (en) | Methods and compositions for modulating th-gm cell function | |
| EP3136078A4 (en) | Cell smearing apparatus and cell smearing method | |
| EP3441982A4 (en) | Joining material and joining method using same | |
| EP3722226A4 (en) | Heat-seal lid and can | |
| EP3556842A4 (en) | Cell culture apparatus and cell culture method | |
| EP3145649A4 (en) | Method and apparatus for utilization of plastic and other waste materials | |
| EP3493597A4 (en) | Switching method and apparatus |